Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension
Biopharmaceutical company Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc. (MLYS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 7,323,750 | $265,778,888 | 2.72% | |
| 2. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 5,871,018 | $213,059,243 | -7% | 21.98% |
| 3. | Caligan Partners David Johnson | 2,772,654 | $100,619,614 | 8.28% | |
| 4. | 2,298,400 | $83,408,936 | 6.87% | ||
| 5. | Laurion Capital Management Benjamin A. Smith | 1,713,485 | $62,182,371 | -1% | 2.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.50 | 588,235 | $14,999,992.50 | 588,235 | 2025-09-04 | Filing | |
| $25.50 | 1,176,470 | $29,999,985.00 | 5,456,521 | 2025-09-04 | Filing | |
| $13.50 | 259,259 | $3,499,996.50 | 8,903,838 | 2025-03-13 | Filing | |
| $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | 2025-03-13 | Filing | |
| $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | 2025-03-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 417 | $10,696.05 | 76,140 | 2026-03-17 | Filing | |
| $27.82 | 253 | $7,038.46 | 76,140 | 2026-03-13 | Filing | |
| $27.37 | 3,079 | $84,264.53 | 76,393 | 2026-03-13 | Filing | |
| $25.91 | 10,726 | $277,922.46 | 79,472 | 2026-03-13 | Filing | |
| $27.37 | 6,348 | $173,747.93 | 82,489 | 2026-03-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,903,838 | $286,830,281 | 92.37% | |
| 2. | 5,057,509 | $183,537,002 | 0.01% | |
| 3. | 4,327,678 | $157,051,434 | 0% | |
| 4. | 3,352,880 | $121,676,015 | 0% | |
| 5. | 3,184,999 | $115,583,614 | 0% |
News See All
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Mineralys Therapeutics, Inc. Fourth Quarter and Full Year 2025 Conference Call. At this time, all participants are in a listen-only mode.
5 Best Day Trading Stocks to Buy Now
Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)'s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock.
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2025 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2025 Earnings Call Transcript November 10, 2025Mineralys Therapeutics, Inc. beats earnings expectations.
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak
Mineralys surged to a new all-time high on Tuesday, as investors gobbled up shares after one of its counterparts posted positive trial results for its aldosterone synthase inhibitor (ASI), with optimism...
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Mineralys Second Quarter 2025 Earnings Call. [Operator Instructions] It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Thank you.
Hedge Fund Resource Center